Loading
Life sciences · Journal article
European Journal Pharmaceutical and Medical Research · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer is a heterogeneous disease with substantial variation in clinical presentation, tumor biology, treatment response, and surgical management. This case series describes five female patients with histologically confirmed invasive breast carcinoma managed at Al-Bairouni University Hospital, Damascus, Syria, during 2026. Patients ranged from 28 to 68 years and presented with breast masses of variable size and extent. Histopathology demonstrated invasive ductal carcinoma, with heterogeneous immunohistochemical profiles, including hormone receptor-positive/HER2-positive, hormone receptor-positive/HER2-negative, triple-negative, and HER2-positive/hormone receptor-negative disease. Three patients received neoadjuvant systemic therapy before definitive surgery, including HER2-directed treatment in HER2-positive tumors. Three patients underwent mastectomy and two underwent breast-conserving surgery, with axillary surgery performed in all cases. One HER2-positive patient achieved pathological complete response, with no residual invasive carcinoma and 0/19 involved lymph nodes. The cases highlight the importance of individualized treatment based on tumor biology, disease extent, treatment response, and multidisciplinary assessment.